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Assessment of prognostic factors in radical radiotherapy
for patients with non-small cell lung cancer
El˝bieta Chmielewska
I n t r o d u c t i o n.  Lung cancer is still the most severe problem of oncology throughout the world. In Poland there are some
20 000 new cases per annum, among them non-small cell lung cancer accounts for about 16 000 cases. The basic method of
therapy of non-small cell lung cancer is surgery; however, in Polish conditions only about 15% of patients qualify for it. The-
refore, there remains a large group of patients who are potential candidates for radiotherapy.
A i m  o f  t h e  s t u d y.  Evaluation of a group of patients qualified for radical radiotherapy according to uniform rules, tre-
ated with the same protocol and assessed by the same group of physicians. The obtained results of therapy allow to evaluate
the usefulness of radical radiotherapy in patients with non-operable non-small cell lung cancer and serve as a basis of search
for more effective radiotherapy protocols. The aim of the study is to attempt to define the prognostic, therapeutical, clinical-
and population-related factors for survival and local control in patients with non-operable, non-small cell lung cancer.
M a t e r i a l  a n d  m e t h o d s.  Between January 1, 1990, and December 31, 1995, there were 2330 patients with non-small
cell lung cancer in the Ambulatory of the Cancer Centre in Warsaw. Basing on the results of clinical examination and addi-
tional examination, 260 patients qualified for radical radiotherapy. In this group there were 31 women (12%) and 229 men
(88%). In a majority of cases the stage of the disease was advanced: stage IIIA was found in 114 patients (44%), and stage
IIIB in 73 patients (28%).
S t a t i s t i c a l  m e t h o d s.  Retrospective analysis of the results of treatment was carried out. The material covered 260 patients.
The survival time and the time to local progression were the basis for the analysis. The survival probability was calculated with
the Kaplan-Meier method. Multidimensional analysis of the prognostic factors (age, clinical advancement of the disease, per-
formance status, loss of weight, LDH and haemoglobin level, tumour size, pulmonary function, prior exploratory thoracoto-
my, presence of selected clinical symptoms) was carried out with D.R. Cox proportional risk model.
R e s u l t s.  Survival probability at two years was 33% ±2% and at five years 10% ±2%. Two-year local control was obta-
ined in 35% ±4% and five-year in 23% ±4% of cases. In the survival analysis the following parameters had significant
influence on the results: stage of the primary tumour – T (p=0.0059), stage of the nodal involvement – N (p=0.0128),
performance status of the patient (p=0.0163), LDH level (p=0.00005), pulmonary function of the patient qualified
for radical radiotherapy (p=0.0053). In local control analysis, significant statistical value was demonstrated for: clinical sta-
ge of the tumour – T (p=0.0259), LDH level (p=0.0002), – pulmonary function of the patient before the treatment
(p=0.0050).
Ocena czynników rokowniczych w radykalnej radioterapii
chorych na niedrobnokomórkowego raka p∏uca
W s t ´ p.  Rak p∏uca jest stale najpowa˝niejszym problemem onkologii na ca∏ym Êwiecie. W Polsce zachorowuje na niego oko-
∏o 20 000 osób rocznie. Z tej grupy oko∏o 16 000 przypadków stanowi rak niedrobnokomórkowy. Podstawowà metodà lecze-
nia niedrobnokomórkowego raka p∏uca jest zabieg chirurgiczny, jednak w warunkach polskich mo˝e byç do niego zakwalifi-
kowanych tylko oko∏o 15% chorych. Z tych przyczyn ciàgle du˝a grupa chorych staje si´ potencjalnymi kandydatami do ra-
dioterapii.
C e l  p r a c y.  Przedmiotem oceny jest grupa chorych, kwalifikowanych do radykalnej radioterapii wed∏ug jednolitych zasad,
leczonych z zastosowaniem tego samego protoko∏u i ocenianych przez t´ samà grup´ lekarzy. Uzyskane wyniki leczenia pozwa-
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Introduction
Lung cancer is still the most severe oncological problem
throughout the world. In Poland there are about 20 000
new cases diagnosed every year. In this group non-small
cell lung cancer accounts for about 16 000 cases. The
basic method of therapy of non-small cell lung cancer
is surgery; however, in Polish conditions only about
15% of patients qualify for it [3-5]. Therefore, the group
of potential candidates for radiotherapy is rather nume-
rous.
Although, according to some authors, radical radio-
therapy allows to obtain tumour regression in as much
as 50% of cases, still five-year survivals constitute merely
3-6% [6-8]. The main reason for failure are dissemination
of the neoplastic process and local recurrence [6, 7, 9-
-15]. Some hope lies in the assessment of the prognostic
factors for this modality. These assessments could contri-
bute to the selection of a group of patients for whom ra-
diotherapy could be an acceptable form of treatment.
The vast majority of papers on this subject suggest univo-
cally that the performance status, stage of the neoplastic
process and weight loss over 10% during the last six mon-
ths before treatment are the most important prognostic
factors in the therapy of non-operative, non-small cell
lung cancer.
Aim of the study
The aim of the study was to attempt to assess both the
known, classical as well as the potential prognostic factors
for patients with non-operative, non-small cell lung cancer
subjected to radical radiotherapy. The results were to se-
rve as a basis for revision and rationalisation of the hither-
to indications for this therapeutical modality in the consi-
dered group of patients.
Material
Between January 1, 1990 and December 31, 1995, 2330 patients
with non-small cell lung cancer called in the ambulatory of
the Institute of Oncology in Warsaw. After examinations 260
patients (31 women (11.9%) and 229 (88.1%) men) aged be-
tween 24 and 79 (mean 61, median 62) qualified for radical ra-
diotherapy.
Clinical stage was assessed according to TNM classification.
In the considered group there were 16 patients (6.2%) in the
I stage and 57 (21.9%) in the II stage. In the majority of cases
the neoplastic process was considerably advanced: stage III
A was found in 114 patients (43,8%) and stage III B in 73 pa-
tients (28.1%).
Blood count and biochemical tests were made for all the
patients. Haemoglobin level before treatment was between 6.2
and 17,2 g/dl (mean 13.4 g/dl, median 13.0 g/dl). Alkaline pho-
sphatase level was assessed in 257 patients (99%). It was be-
tween 10 and 353 IU/l (mean 107.8 IU/l, median 98 IU/l). LDH
level was assessed in 214 patients (82.3%) and it was between 60
and 531 IU/l (mean 194.1 IU/l, median 176 IU/l). In 200 pa-
tients chest tomography was performed to assess the tumour
size, in 47 other patients the information on the size of the lesion
came form the description during exploratory thoracotomy. In
the remaining patients the tumour size was estimated from the
chest X-ray. The largest transversal dimension of the tumour
was between 10 mm and 90 mm (mean 54 mm, median 50 mm).
Clinical characteristics
The overall performance status score was assessed ac-
cording to Zubrod. In the group there were 19 patients
with score 0 (7.3%), 216 with score 1 (83%) and 25 with
score 2 (9.6%).
During the first clinical examination the presence
of the following clinical symptoms was assessed: ha-
emoptysis, hoarseness, intensive cough and chest ache
necessitating pharmacological management, and dyspno-
ea with exertion when climbing two flights of stairs. The-
se symptoms were treated as the analysed prognostic
lajà okreÊliç przydatnoÊç radykalnej radioterapii u chorych na nieoperacyjnego, niedrobnokomórkowego raka p∏uca i sà pod-
stawà do poszukiwaƒ skuteczniejszych programów leczenia napromienianiem. 
Celem pracy jest próba okreÊlenia czynników prognostycznych, kliniczno-populacyjnych i terapeutycznych dla prze˝yç i miej-
scowego wyleczenia chorych na nieoperacyjnego, niedrobnokomórkowego raka p∏uca.
M e t o d y  s t a t y s t y c z n e.  Przeprowadzono retrospektywnà analiz´ wyników leczenia. Materia∏ obejmowa∏ informacje
o 260 chorych. Podstawà oceny wyników by∏ czas prze˝ycia oraz czas do wystàpienia progresji miejscowej. Prawdopodobieƒ-
stwo prze˝ycia obliczano metodà Kaplana-Meiera. Wielowymiarowà analiz´ czynników prognostycznych (wiek, stopieƒ kli-
nicznego zaawansowania choroby, stopieƒ sprawnoÊci, utrata masy cia∏a, poziom dehydrogenazy mleczanowej i hemoglobi-
ny, wielkoÊç guza, stopieƒ wydolnoÊci oddechowej, fakt przebycia torakotomii zwiadowczej, obecnoÊç wybranych dolegliwo-
Êci) przeprowadzono u˝ywajàc modelu proporcjonalnego ryzyka D.R. Cox'a.
W y n i k i.  Prawdopodobieƒstwo dwuletniego prze˝ycia chorych wynios∏o 33% ±2%, a pi´cioletniego 10% ±2%. Prawdo-
podobieƒstwo dwuletniego miejscowego wyleczenia wynios∏o 35% ±4%, a pi´cioletniego 23% ±4%. W analizie prze˝yç na-
st´pujàce parametry mia∏y istotny wp∏yw na uzyskane wyniki: stopieƒ zaawansowania guza pierwotnego – cecha T (p=0,0059),
stopieƒ zaj´cia regionalnych w´z∏ów ch∏onnych – cecha N (p=0,0128), – stopieƒ sprawnoÊci chorego (p=0,0163), poziom de-
hydrogenazy mleczanowej (p=0,00005), wydolnoÊç oddechowa chorego kwalifikowanego do radykalnej radioterapii
(p=0,0053). W analizie miejscowej wyleczalnoÊci znamiennà wartoÊç statystycznà wykazano dla: stopnia zaawansowania kli-
nicznego guza – cecha T (p=0,0259), poziomu dehydrogenazy mleczanowej (p=0,0002), wydolnoÊci oddechowej chorego
przed leczeniem (p=0,0050).
Key words: radical radiotherapy, prognostic factors, non-small cell lung cancer
S∏owa kluczowe: radykalna radioterapia, czynniki prognostyczne, niedrobnokomórkowy rak p∏uca
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factors. The time of appearance of these symptoms was
not recorded.
Weight loss during the six months before the treat-
ment was reported by 98 patients (37.7%). Losses were
from 1 kg to 20 kg (mean 2.25 kg). In 67 patients (25.8%)
a loss of at least 5 kg was noticed. In a group of 260 pa-
tients, in 47 (18%) before the irradiation an exploratory
thoracotomy was performed. All these interventions we-
re performed outside of the Center of Oncology.
In a majority of patients the thoracosurgeons car-
ried out pulmonary function tests. In 63 patients disquali-
fied from surgery the features of dyspnoea were found.
These patients were treated with radical radiotherapy
and underwent a detailed analysis in the present study.
Method of treatment
The patients with the following characteristics qualified
for radical irradiation: good general condition, no signifi-
cant dyspnoea (easily climbs two flights of stairs), witho-
ut severe circulatory insufficiency resistant to treatment,
with no weight loss over 10% during last six months. Pa-
tients with local advancement, with no involvement of
the supraclavicular lymph nodes, with no oesophagus in-
filtration and with no infiltration of the entire wall of the
myocardium, the chest wall and the spine (excluding the
Pancoast tumour), with no presence of the neoplasmatic
cells in the pleural or pericardial cavity liquid were subjec-
ted to treatment. The basic qualification criterion was
the tumour size. Patients with transversal dimension of
the tumour of up to 6-7 cm were treated.
The irradiation treatment was carried out according
to a uniform treatment protocol, under the supervision of
the same group of physicians. Treatment was carried out
in two stages. In the first stage a 44-46 Gy dose was admi-
nistered to the tumour site with the neighbouring me-
diastinum using the AP fields. In the second stage the
dose to the tumour was increased up to 64-69 Gy, with the
use of the oblique fields, while avoiding the spinal cord.
The technique of large fields, i.e., the fields including the
tumour and the neighbouring mediastinum region was
applied to 234 patients. A 2 cm margin of normal tissue
around the tumour and the involved mediastinum lymph
nodes was added. The mediastinum of the normal side
was surrounded by a 1 cm margin on the left in the case of
a right lung tumour and a 2 cm margin on the right in the
case of a tumour in the left lung. In nine cases the suprac-
lavicular region on the side of the tumour was included
due to a tumour of lung top. In 26 patients (10%) the
treatment was carried out with small fields including the
tumour and the nearest lymph nodes. This was the group
in which the general state or impaired pulmonary function
created a risk of severe complications. For all the pa-
tients the total dose was calculated according to the
ICRU recommendations in the middle of the AP dimen-
sion in the central radius for the AP fields and in the iso-
centre for the oblique fields.
Conventional irradiation, 2 Gy per day, 5 times per
week was applied to 254 patients. Also 6 patients in who-
se cases the first stage of treatment was carried out with
nonconventional fractionation were included in the ana-
lysis. This group initially qualified for palliative therapy. In
this group after the first stage of treatment significant
tumour regression was observed in the computer tomo-
graphy tests and qualification was changed from pallia-
tive to radical. The equivalent dose for the first stage of
treatment was recalculated with the linear-quadratic
formula.
Irradiation was carried out with the Cobalt 60 gam-
ma beams or photon X beams with energies of 4, 9 and 15
MeV obtained in linear accelerators. In the cases where
the first stage of treatment was performed with Cobalt or
photons of 4 MeV, the second stage was carried out with
higher energy.
Methods of analyses
The source for the retrospective analysis of the clinical
material were the case histories. Observation closed on
December 31, 1999. For all the patients the information
whether the patient was alive, and if not, the date of de-
ath was known. The material comprised information on
260 patients. The basic information for the assessment of
results was the survival time and time to local progres-
sion. The local progression was assessed from the chest
X-ray. The survival time was measured from the star-
ting date of irradiation to the date of death or of the
last information that the patient lives. Time to local pro-
gression was measured form the starting date of irra-
diation to the date of finding the features of progres-
sion or, if the progression was not found, the date of
the last clinical examination. Survival probability was
calculated with the Kaplan-Meier method [16]. Local
control has been defined as the probability of non-occur-
rence of the local progression. Multivariant analysis of
prognostic factors has been carried out with the use of
the D.R. Cox proportional risk model [17]. The func-
tion of death risk and the function of local progression
occurrence was modelled. The following classical pro-
gnostic factors were included in the model: age, tumour
stage T, regional lymph nodes involvement stage N, Zu-
brod performance status, weight loss during the last six
months, lactate dehydrogenase level (LDH) and haemo-
globin level (HB). The significance of the following po-
tential prognostic factors was investigated: tumour size,
pulmonary function, prior exploratory thoracotomy, exi-
stence of selected clinical symptoms before treatment
(cough, chest ache necessitating for management, dysp-
noea with exertion). The definition of the analysed para-
meters is shown in Table I. The final form of the model
has been obtained by stepwise elimination of variables
for which the test critical level was larger than 0.1
(p>0.1). The statistical significance α=0,05 was assu-
med. The assumptions of the model were verified with
the graphic methods.
Tolerance of the treatment was assessed. Post-irra-
diation reaction intensity was scored with the
RTOG/EORTC scale [18, 19].
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Results
S u r v i v a l
Observation period varied between 2 and 98 months (me-
dian 16 months). In the tested group 230 patients died. In
196 cases in the last clinical examination the features of
the disease were found (75%). Among 64 patients who
died without features of the disease, according to the last
examination, in 15 cases the reason of death was found: in
9 cases the direct reason was myocardial infarct, in one ca-
se it was stroke without features indicating metastases
(the patient had no computer tomography of the brain
and the diagnosis was made on the basis of neurological
examination), in two cases the reason was a car accident,
in two – suicide, in one – stomach perforation. It can not
be excluded that in the remaining cases the reason of de-
ath was the recurrence or the post-irradiation effect.
The two-year survival in the whole group was
33%±2%, and the five-year survival was 10%±2%. Two-
-year local control was estimated as 35%±4% and the
five-year one as 23%±4%. The results obtained are pre-
sented in Table II and Figures 1 and 2.
Tab. I. Characteristics of the material and coding of the analysed variables
Analysed variable Coding N (%)
Age at the time of diagnosis WIEK 260 (100)
AGE ≤58 1 88 (33.8)
58 < AGE ≤66 2 97 (37.3)
AGE > 66 3 75 (28.8)
Clinical stage T T 260 (100)
T1 1 14 (5.4)
T2 2 99 (38.1)
T3 3 77 (29.6)
T4 4 70 (26.9)
Clinical stage N N 260 (100)
N0 0 25 (9.6)
N1 1 118 (45.4)
N2 2 111 (42.7)
N3 3 6 (2.3)
Performance status according to Zubrod ZUBROD 260 (100)
0 0 19 (7.3)
1 1 216 (83.1)
2 2 25 (9.6)
Weight loss during last
6 months UW 260 (100)
UW = 0 1 162 (62.3)
0 < UW ≤5 2 53 (20.4)
UW > 5 3 45 (17.3)
LDH level LDH 214 (100)
LDH (120 1 72 (33.6)
120 < LDH ≤232 2 72 (33.6)
LDH > 232 3 70 (32.8)
Haemoglobin level HB 260 (100)
HB 12.8 1 82 (31.6)
12.8 < HB ≤14.3 2 89 (34.2)
HB > 14.3 3 89 (34.2)
Size of the tumour WLKG 260 (100)
WLKG (40 1 49 (18.8)
40 < WLKG ≤60 2 157 (60.4)
WLKG > 60 3 54 (20.8)
Impaired pulmonary function MALAWYD 2 60 (100)
NO 0 197 (75.8)
YES 1 63 (24.2)
Thoracotomy THORACO 260 (100)
NO 0 213 (81.9)
YES 1 47 (18.1)
Cough KASZEL 260 (100)
YES 1 113 (43.5)
NO 2 147 (56.5)
Ache BOL 260 (100)
YES 1 56 (21.5)
NO 2 204 (78.5)
Dyspnoea DUSZ 260 (100)
YES 1 67 (25.8)
NO 2 193 (74.2)
Haemoptysis KRWIOPL 260 (100)
YES 1 98 (37.7)
NO 2 162 (62.3)
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P r o g n o s t i c  f a c t o r s
The influence of the following classical prognostic
factors on the survival has been confirmed: tumour
stage T (p=0.0059), lymph node involvement stage
N (p=0.128), performance status of the patient
(p=0.0163), and lactate dehydrogenase level (p<0.00005).
The parameters of the chosen model of the death risk
are shown in Table III. The following factors were exclu-
ded from the model (p>0.1): age, weight loss, tumour
size, prior exploratory thoracotomy, clinical symptoms.
In the group of potential factors the influence of only
one factor on the survival was confirmed: pulmonary
function (p=0.0053). Patients with impaired pulmonary
function had an over 1.5 times greater death risk than
those with normal pulmonary function.
In the analysis of local control a significant statistical
value of the following classical factors was found: tumour
advancement stage T (p=0.0259) and lactate dehydro-
genase level (p=0.0002). The parameters of the assumed
model of local progression risk are shown in Table IV.
The following factors were excluded from the model
(p>0.1): age, advancement level N, performance status of
the patient, weight loss, haemoglobin level, tumour size,
prior exploratory thoracotomy, other clinical symptoms.
From the potential factors only the pulmonary function
appeared to be statistically significant for local control
(p=0.0050). The patients with reduced pulmonary func-
tion had a nearly two times larger risk of local progres-
sion. The influence of the other factors was not statistical-
ly significant.
It should be pointed out that the advancement stage
T, lactate dehydrogenase level and pulmonary function
had significant influence on the long-term survival as well
as on the local control.
To l e r a n c e  o f  t r e a t m e n t
During radiotherapy acute postirradiation reaction ap-
peared in 70 patients (27%), mainly oesophagitis, short-
ness of breath and leukopoenia and thrombocytopoenia,
including 11 patients (4.6%) in which it was assessed as
damage III°. Late sequelae were found in 9 patients
(3.7%). In 5 patients it was prolonged shortness of breath
while walking on the level, necessitating for pharmacothe-
rapy (II°). In 3 patients (1.1%) there was dysphagia as
a result of postirradiation oesophagus obstruction, ne-
cessitating for surgical intervention (III°). In one patient
(0.3%) postirradiation damage of the spinal cord in the
form of paraparesis (IV°) appeared. This patient rece-
Fig. 1. Survival probability in 260 patients with non-small cell lung can-
cer subjected to radical radiotherapy alone
Fig. 2. Local control probability in 260 patients with non-small cell
lung cancer subjected to radical radiotherapy alone
Tab. II. Survival and local control probability with the 95% confidence
interval
Time of observation Survival probability Local control probability
(months) (95% CI) (95% CI)
12 0.60 (0.54; 0.66) 0.64 (0.58; 0.70)
24 0.33 (0.29; 0.37) 0.35 (0.27; 0.43)
60 0.10 (0.06; 0.14) 0.23 (0.15; 0.31)
Pr
oa
bi
ty
Pr
oa
bi
ty
Follow-up (months) Follow-up (months)
Tab. III. Parameters of the assumed death risk model (Cox model)
Variable Coefficient β Standard error βCritical level p Relative risk
T 0.2561 0.0930 0.0059 1.2919
N 0.3121 0.1254 0.0128 1.3662
ZUBROD 0.4090 0.1703 0.0163 1.5053
LDH 0.6046 0.0947 <0.00005 1.8305
HB -0.1598 0.0946 0.0913 0.8523
MALAWYD 0.5192 0.1862 0.0053 1.6807
Tab. IV. Parameters of the assumed local progression risk model
(Cox model)
Variable Coefficient β Standard error βCritical level p Relative risk
T 0.2604 0.1168 0.0259 1.2974
LDH 0.4468 0.1190 0.0002 1.5633
MALAWYD 0.6527 0.2327 0.0050 1.9207
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ived the total dose of 47.3 Gy administered to 11 cm of
spinal cord.
Discussion
An assessment of prognostic factors in radical radiothe-
rapy administered alone has been carried out for a group of
260 patients with non-operative, non-small cell lung cancer.
The results of the analysis make it possible to state
that radical radiotherapy applied as the only method of
treatment in the group of patients with non-small cell
nonoperative lung cancer is the most profitable for pa-
tients with good general performance status – Zubrod 0
or 1, with good pulmonary function and with a non-advan-
ced tumour. Biochemical tests planned in diagnostic and
qualification process should include the lactate dehydro-
genase level. Most of the authors concentrate on the pul-
monary function. According to them radical radiotherapy
can be safely performed only for patients with proper
pulmonary function [6, 20-24]. However, the assessment
of proper pulmonary function with the exertion test of
climbing two flights of stairs is not precise.
Many authors point out that age, performance status
and weight loss over 10% during last 3-6 months before
the treatment are significant prospective factors [10, 25-
-28]. It has been demonstrated that age over 60 and in
other studies – 65 is an unfavourable prognostic factor.
Wigren did not demonstrate a significant dependence of
the results on the age of patients [15]. In Bauer's study
[25] high statistical significance of the general perfor-
mance status was shown (p=0.001). In the investigation
by Sause et al. [29] mean survival of patients with perfor-
mance status less or equal to 70 points according to Kar-
nofsky (KPS) was 5.9 months, and with over 70 points –
9.9 months. According to most of the authors, radical ra-
diotherapy can be applied in patients without weight loss
over 10% during last 6 months [21, 25, 27].
In the present study the performance status scored
according to Zubrod appeared to be a significant parame-
ter in the analysis of long-term survival (p=0.016), while
it was found to be insignificant in the assessment of local
recurrences (p=0.8). The age and weight loss was not fo-
und to be statistically significant.
In the studies published in the 90's a vast majority of
authors underline a significant prognostic value of the
stage of the disease [10, 14, 15, 26, 27, 29]. Emami et al.
reported that in the studies carried out in the 70's and
80's this parameter had an ambiguous value [30].
In the analysed group of patients this factor appe-
ared to be statistically significant both for the death risk
function and the local recurrence function.
In many studies haemoglobin and lactate dehydroge-
nase level were taken into account as prognostic factors
[15, 26, 27, 31, 32]. Haemoglobin concentration is a para-
meter which influences the radiosensitivity of tissues and
makes it possible to assess their oxygenation factor. Toge-
ther with better oxygenation, larger local control has be-
en observed. The relation of the radiotherapy results and
the oxygenation factor of tissues has been demonstrated
in many studies, mainly those on head and neck neopla-
sms [33-35]. Lactate dehydrogenase increase in the blood
serum indicates the presence of foci of necrosis in the
organism, increased permeability of cell membrane or
the presence of quickly growing tissues. Neoplasmatic
cells have increased permeability for lactate dehydrogena-
se and a significant growth of its level suggests the presen-
ce of a large neoplasmatic mass [31]. Because of this, in-
directly, the lactate dehydrogenase level in the blood se-
rum can be a sign of presence of a large neoplasmatic
mass and presence of subclinical cancer foci. In this ana-
lysis the haemoglobin level appeared not to be signifi-
cant for local recurrence risk (p=0.4) as well as for long-
-term survival (p=0.09). Difficulties in assessment of this
parameter result from the fact that the majority of pa-
tients had proper haemoglobin level. In the analysis of
lung cancer therapy studies it should be taken into acco-
unt that the majority of patients are long-term smokers in
whom a chronic, obturative lung disease develops. This di-
sease is the reason for impairment of pulmonary func-
tion, which stimulates the marrow reaction in form of
poliglobulia. As a result, the haemoglobin level can be
high, as found in the analysed group of patients, while
the oxygenation of tissues is low. The lactate dehydroge-
nase level appeared to be strongly significant for the re-
sults of treatment of the analysed group of patients.
In the analysis of the potential factors the tumour si-
ze was investigated. This parameter was the basic sub-
ject of assessment in the RTOG 73-01 study, the results of
which were published for the first time by Perez et al.
[36]. In this four-arm study comprising 378 patients the
dependence of treatment results on the administered to-
tal dose and tumour size was prospectively assessed. The
largest cure percentages were obtained in the case of tu-
mours smaller than 3 cm, and the smallest percentages –
when the transversal dimension of the lesion was larger
than 6 cm. Katz [37] and Martel [38] published similar re-
sults. In the latter experiment the tumour size was asses-
sed in three dimensions. In the cases when the tumour vo-
lume was smaller than 200 cm3 the statistically longer su-
rvivals were demonstrated (p=0.047). In that study the
statistical significance of this parameter was not demon-
strated.
An important parameter in the group of the poten-
tial parameters tested in the present analysis was the pul-
monary function level. Usually much worse tolerance of
treatment is observed in patients with pulmonary dys-
function. According to the majority of the authors radical
radiotherapy can be safely carried out only in patients
with proper pulmonary function [6, 20, 22, 24]. Unfortu-
nately, in none of these studies the diffusion ability of
lungs or the partial pressure of oxygen and carbon dioxi-
de was tested. A good pulmonary function was scored in
relation to easily climbing two flights of stairs. In the pre-
sent analysis a statistically significant influence of this
factor on the long-term survival (p=0.0053) as well as on
the local recurrence risk (p=0.0050) was demonstrated.
In the analysis of the prognostic factors it has also
been attempted to assess the influence of the presence of
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selected clinical symptoms, reported by the patients befo-
re the therapy, on the results of the treatment. Shortage
of breath while climbing two flights of stairs, cough and
chest ache necessitating for pharmacological manage-
ment, and haemoptysis have been analysed. The influ-
ence of the above parameters was studied by Wigren [15].
He has also analysed the performance status of the pa-
tients, stage of the disease and haemoglobin level. Wi-
gren has demonstrated that each of these factors, inclu-
ding the symptoms, reduces the probability of 24 months
survival by 13%. In the present work the influence of the
clinical symptoms on the results of treatment has not be-
en confirmed.
In the analysis of the prognostic factors also the prior
exploratory thoracotomy has been taken into account.
Surgery reduces the oxygenation of tissues in the region of
the operation, hence having a potentially negative influen-
ce on treatment results. The value of this factor appe-
ared not to be significant in the analysis, either for the
long-term survival (p=0.3) or for the local recurrence
risk (p=0.3).
In spite of the fact that age and weight loss did not ap-
pear to have a significant influence on the results of treat-
ment, it seems that these parameters should be properly ta-
ken into account in the assessment of the performance
status of a patient qualified for radical radiotherapy.
The still unsatisfactory results of treatment of pa-
tients with non-small cell lung cancer are a constant chal-
lenge for oncologists and constitute an incentive for a fu-
ture search of more efficient methods of therapy.
Conclusion
1. Multivariant statistical analysis has demonstrated that
the independent prognostic factors in a group of pa-
tients with nonoperative, non-small cell lung cancer
subjected to radical radiotherapy are:
- for survival: clinical stages T and N, pulmonary func-
tion, performance status of the patient and lactate de-
hydrogenase level assessed before treatment;
- for local control: clinical stage T, lactate dehydroge-
nase level assessed before treatment and pulmonary
function.
2. Patients with impaired pulmonary function have a 1.5
times larger death risk and a nearly two times larger
risk of local recurrence.
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